RxDoctor Payments Data

Edward Chen, MD

Anesthesiology · Clearwater, FLNPI 1184642902

Payments from drug & device makers

$11,454in general payments, 2019–2025

Across 330 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Nevro Corp.$1K
  • Stimwave Technologies Incorporated$897
  • Collegium Pharmaceutical, Inc.$797
  • Surgentec$429
  • Tersera Therapeutics LLC$404
  • plus $2K from 33 others

What the payments were for

  • Consulting fees$3253%
  • Travel & lodging$3,46230%
  • Food & beverage$7,54966%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,454 in reported general payments places this provider in the 95th percentile of 2,767 anesthesiology providers in Florida.

See all anesthesiology providers in Florida

Medicare billing

Part B allowed, 2024
$539,712
Medicare patients
547
Services billed
18,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate47$35,665
Fentanyl119$17,770
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen471$15,898
Oxymorphone Hcl ErOxymorphone Hcl11$13,195
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen515$10,981
Morphine Sulfate ErMorphine Sulfate227$7,506
Oxycodone Hcl194$4,776
Morphine Sulfate112$2,474
Tramadol Hcl158$1,666
Gabapentin128$1,664
Hydromorphone Hcl73$1,603
Lidocaine22$1,564
Naloxone Hcl22$1,327
Pregabalin41$1,070
Methadone Hcl43$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$797$35,66547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,767 anesthesiology providers in Florida.

Other anesthesiology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →